Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials

Arvinas Inc. (NASDAQ:ARVN) is one of the best cancer stocks to invest in now. On February 24, Arvinas Inc. (NASDAQ:ARVN) ...
Seeking Alpha

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced ...
Nasdaq

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

– The Company recently initiated a Phase 1 trial with PROTAC LRRK2 degrader ARV-102 in patients with Parkinson’s disease – – Data disclosures anticipated from multiple clinical and pre-clinical ...
Business Insider

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

NEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
The Manila Times

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 - ...